- Stocks
- Healthcare
- NASDAQ: MRNA

Price (delayed)

$130.51

Market cap

$49.75B

P/E Ratio

10.64

Dividend/share

N/A

EPS

$12.27

Enterprise value

$47.24B

Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert

The quick ratio has soared by 99% YoY and by 25% from the previous quarter

The equity is up by 10% YoY

The debt has grown by 25% year-on-year but it has declined by 8% since the previous quarter

The net income has plunged by 67% YoY and by 43% from the previous quarter

The company's EPS has shrunk by 66% YoY and by 42% QoQ

What are the main financial stats of MRNA

Market
Valuations
Earnings

Shares outstanding

381.21M

Market cap

$49.75B

Enterprise value

$47.24B

Price to earnings (P/E)

10.64

Price to book (P/B)

2.67

Price to sales (P/S)

3.35

EV/EBIT

9.37

EV/EBITDA

8.77

EV/Sales

3.14

Revenue

$15.06B

EBIT

$5.04B

EBITDA

$5.39B

Free cash flow

$612M

Per share
Balance sheet
Liquidity

EPS

$12.27

Free cash flow per share

$1.59

Book value per share

$48.82

Revenue per share

$39.01

TBVPS

$62.5

Total assets

$24.13B

Total liabilities

$5.26B

Debt

$927M

Equity

$18.86B

Working capital

$8.62B

Debt to equity

0.05

Current ratio

3.46

Quick ratio

2.87

Net debt/EBITDA

-0.47

Margins
Efficiency
Dividend

EBITDA margin

35.8%

Gross margin

65.5%

Net margin

31.8%

Operating margin

32.1%

Return on assets

18.7%

Return on equity

25.9%

Return on invested capital

28.3%

Return on capital employed

24.4%

Return on sales

33.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Moderna stock price performed over time

Intraday

1.55%

1 week

3.38%

1 month

-0.68%

1 year

-6.9%

YTD

-27.34%

QTD

-15.02%

How have Moderna's revenue and profit performed over time

Revenue

$15.06B

Gross profit

$9.87B

Operating income

$4.83B

Net income

$4.78B

Gross margin

65.5%

Net margin

31.8%

The operating income has plunged by 70% YoY and by 49% from the previous quarter

The net income has plunged by 67% YoY and by 43% from the previous quarter

Moderna's operating margin has shrunk by 55% YoY and by 34% QoQ

The net margin has dropped by 51% year-on-year and by 27% since the previous quarter

What is Moderna's growth rate over time

What is Moderna stock price valuation

P/E

10.64

P/B

2.67

P/S

3.35

EV/EBIT

9.37

EV/EBITDA

8.77

EV/Sales

3.14

The company's EPS has shrunk by 66% YoY and by 42% QoQ

The stock's P/E is 46% above its last 4 quarters average of 7.3

MRNA's P/B is 63% below its 5-year quarterly average of 7.2 and 14% below its last 4 quarters average of 3.1

The equity is up by 10% YoY

The stock's P/S is 94% below its 5-year quarterly average of 52.6 but 8% above its last 4 quarters average of 3.1

MRNA's revenue is down by 33% year-on-year and by 22% since the previous quarter

How efficient is Moderna business performance

The ROIC has plunged by 86% YoY and by 50% from the previous quarter

MRNA's return on equity has dropped by 79% year-on-year and by 44% since the previous quarter

Moderna's ROA has plunged by 71% YoY and by 41% from the previous quarter

The company's return on sales has shrunk by 53% YoY and by 33% QoQ

What is MRNA's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for MRNA.

How did Moderna financials performed over time

The quick ratio has soared by 99% YoY and by 25% from the previous quarter

The current ratio has surged by 95% year-on-year and by 27% since the previous quarter

The debt is 95% smaller than the equity

The company's debt to equity rose by 25% YoY

The debt has grown by 25% year-on-year but it has declined by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.